Tree, A. C., Ostler, P., van der Voet, H., Chu, W., Loblaw, A., Ford, D., Tolan, S., Jain, S., Martin, A., Staffurth, J., Armstrong, J., Camilleri, P., Kancherla, K., Frew, J., Chan, A., Dayes, I. S., Duffton, A., Brand, D. H., Henderson, D., Morrison, K., Brown, S., Pugh, J., Burnett, S., Mahmud, M., Hinder, V., Naismith, O., Hall, E., van As, N., , , Lartigau, E., Patton, S., Thompson, A., Winkler, M., Wells, P., Lymberiou, T., Saunders, D., Vilarino-Varela, M., Vavassis, P., Tsakiridis, T., Carlson, R., Rodrigues, G., Tanguay, J., Iqbal, S., Winkler, M., Morgan, S., Mihai, A., Li, A., Din, O., Panades, M., Wade, R., Rimmer, Y., Panades, M., & Oommen, N. (2022). intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial. Lancet oncology, 23(10), 1308–1320. http://access.bl.uk/ark:/81055/vdc_100166754737.0x000014